| (Values in U.S. Thousands) | Mar, 2024 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Sep, 2022 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,903 | -1,323 | -1,131 | -5,490 | -9,958 |
| Net Income Growth | -43.85% | -16.97% | +79.40% | +44.86% | -61.95% |
Fsd Pharma Inc Subordinate Voting Share (HUGE.CN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.1250 -0.0200 (-13.79%) 08/14/24 [CNSX]
N/A x N/A N/A x N/A
Post-market 0.1250 unch (unch) -
for Wed, Aug 14th, 2024
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.